Back to 128th Annual Meeting
Back to Program Outline

OBJECTIVE(S):
We analyzed a single center’s experience over a decade of right liver living donor liver transplantation (LDLT).
METHODS:
Consecutive patients from 9 May 1996 were included. Era I comprised the first 50 patients and Era II the remaining 184. Deceased donor liver transplantation (DDLT) outcomes of the same period in the same center were used for comparison.
RESULTS:
With a median follow-up of 48 months, the 1-, 3-, and 5-year overall survivals were 93.2%, 85.7%, and 82.4% and were comparable to DDLT (n=131) of the same period (89.3%, 86.6%, and 83.5%) (p=0.876). The hospital mortality decreased from 16% in Era I to 2.2% in Era II (p = 0.000). Reduced hospital mortality improved survivals from Era I to II (78%, 74%, and 72% versus 97.3%, 88.7%, and 85.1%, respectively) (p=0.003). The 5-year survival of recipients with HCC within the Milan criteria (n=42) was 69.6%. Multivariate analysis indicated that only Era I (RR=2.606, p=0.005) and pre-transplant HCC (RR=2.729, p=0.002) adversely affecting overall survival and disregard emergent LDLT and recipient Model-for-End-stage Liver Disease scores.
Starting from Era II, excellent 5-year survival of recipients without HCC was achieved as compared with DDLT in the same period (93.4% versus 88.2%) (p=0.493). The 5-year survival rates of recipients with HCC within the Milan criteria for Era II and DDLT in the same period were 72.0% and 100%, respectively (p=0.091).
CONCLUSIONS:
High mid-term survivals are achieved by reduction of hospital mortality through accumulation of experience and transplanting recipients with low chance of recurrence of HCC.

Back to 128th Annual Meeting
Back to Program Outline